Literature DB >> 7934448

Interferon beta-1b.

D E Goodkin1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7934448     DOI： 10.1016/s0140-6736(94)91713-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 2.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 3.  Towards cytokine insight in sight.

Authors:  J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

Review 4.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Recent developments in multiple sclerosis therapeutics.

Authors:  Rebecca I Spain; Michelle H Cameron; Dennis Bourdette
Journal:  BMC Med       Date:  2009-12-07       Impact factor: 8.775

Review 6.  Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.

Authors:  Serena Ruggieri; Carla Tortorella; Claudio Gasperini
Journal:  Ther Clin Risk Manag       Date:  2014-03-27       Impact factor: 2.423

Review 7.  Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.

Authors:  Catharina Korsukewitz; Stephen W Reddel; Amit Bar-Or; Heinz Wiendl
Journal:  Nat Rev Neurol       Date:  2020-07-08       Impact factor: 44.711
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.